FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine)
662  

FDA approves ViiV Healthcare’s Dovato (dolutegravir/lamivudine)

The U.S. Food and Drug Administration approved Dovato (dolutegravir and lamivudine), as a complete regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults with no antiretroviral treatment history and with no known or suspected substitutions associated with resistance to the ...

April 10, 2019
News  
FDA Grants Fast Track Designation to Hepatitis B Drug
691  

FDA Grants Fast Track Designation to Hepatitis B Drug

The FDA recently granted Fast Track designation to Assembly Biosciences, Inc’s novel treatment for patients with chronic hepatitis B virus (HBV) infection. The drug, ABI-H0731, is the manufacturer’s lead oral HBV core inhibitor, according to a press release.

August 07, 2018
News